Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database
Journal of Surgical Oncology · 2023-08 · 128 (2) · 262-270
DOI: 10.1002/jso.27280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 12.04.2023. Verfasst von Sarah R Kaslow und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Liver Neoplasms, Neoplasms, Second Primary, Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
There is no consensus regarding the role of primary tumor resection for patients with metastatic pancreatic neuroendocrine tumors (panNET). We assessed surgical treatment patterns and evaluated the survival impact of primary tumor resection in patients with metastatic panNET.
Methods
Patients with synchronous metastatic nonfunctional panNET in the National Cancer Database (2004−2016) were categorized based on whether they underwent primary tumor resection. We used logistic regressions to assess associations with primary tumor resection. We performed survival analyses with Kaplan−Meier survival functions, log‐rank test, and Cox proportional hazard regression within a propensity score matched cohort.
Results
In the overall cohort of 2613 patients, 68% ( n = 839) underwent primary tumor resection. The proportion of patients who underwent primary tumor resection decreased over time from 36% (2004) to 16% (2016, p < 0.001). After propensity score matching on age at diagnosis, median income quartile, tumor grade, size, liver metastasis, and hospital type, primary tumor resection was associated with longer median overall survival (OS) (65 vs. 24 months; p < 0.001) and was associated with lower hazard of mortality (HR: 0.39, p < 0.001).
Conclusion
Primary tumor resection was significantly associated with improved OS, suggesting that, if feasible, surgical resection can be considered for well‐selected patients with panNET and synchronous metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA.
- Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Zitieren
APA
Kaslow, S. R., Hani, L., Cohen, S. M., Wolfgang, C. L., Sacks, G. D., Berman, R. S., Lee, A. Y., & Correa-Gallego, C. (2023). Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database. Journal of Surgical Oncology, 128(2), 262-270. https://doi.org/10.1002/jso.27280
Vancouver
Kaslow SR, Hani L, Cohen SM, Wolfgang CL, Sacks GD, Berman RS, et al. Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database. Journal of Surgical Oncology. 2023;128(2):262-270. doi:10.1002/jso.27280
BibTeX
@article{Kaslow2023,
author = {Kaslow, Sarah R and Hani, Leena and Cohen, Steven M and Wolfgang, Christopher L and Sacks, Greg D and Berman, Russell S and Lee, Ann Y and Correa-Gallego, Camilo},
title = {Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database},
journal = {Journal of Surgical Oncology},
year = {2023},
volume = {128},
number = {2},
pages = {262--270},
doi = {10.1002/jso.27280}
}
EUVIMED